Showing 5261-5270 of 5644 results for "".
- Pioneering Ophthalmologist Patricia Bath, MD, Dies at 76https://modernod.com/news/pioneering-ophthalmologist-patricia-bath-md-dies-at-76/2476632/Patricia E. Bath, MD, an ophthalmologist who took a special interest in combating preventable blindness in underserved populations and became the first black female doctor to patent a medical invention, a laser device for treating cataracts, died at the age of 76, acc
- Allegro Ophthalmics Announces Positive Topline Results of Phase 2 Study Evaluating Risuteganib in Patients with Intermediate Dry AMDhttps://modernod.com/news/allegro-ophthalmics-announces-positive-topline-results-of-phase-2-study-evaluating-risuteganib-in-patients-with-intermediate-dry-amd/2476627/Allegro Ophthalmics announced positive topline results of its phase 2 study of risuteganib (Luminate) for the treatment of intermediate dry age-related macular degeneration (AMD). The clinical trial met its primary endpoint with 48 percent of patients in the risuteganib arm gaining ≥ 8 letters of
- Re-Vana Therapeutics Names International Experts to Inaugural Scientific Advisory Boardhttps://modernod.com/news/re-vana-therapeutics-names-international-experts-to-inaugural-scientific-advisory-board/2476628/Re-Vana Therapeutics announced the formation of its new Scientific Advisory Board (SAB). The newly appointed SAB will strategically advise and support Re-Vana as it develops innovative therapies for a broad range of ophthalmic indications, including wet age-related macular degeneration (AMD), dia
- Precision Medicine to Prevent Glaucoma-Related Blindnesshttps://modernod.com/news/precision-medicine-to-prevent-glaucoma-related-blindness/2476617/Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine.
- Study: 3D Printed Artificial Corneas Similar to Human Oneshttps://modernod.com/news/study-3d-printed-artificial-corneas-similar-to-human-ones/2476615/When a person has a severely damaged cornea, a corneal transplant is required. However, there are 2,000 patients waiting for the cornea donation in the country as of 2018, and they wait for 6 or more years on average for the donation. For this reason, many scientists have put their efforts in dev
- Central Retinal Vein Occlusion Rarely Complicates Ulcerative Colitishttps://modernod.com/news/central-retinal-vein-occlusion-rarely-complicates-ulcerative-colitis/2476609/Central retinal vein occlusion (CRVO) can rarely complicate the course of inflammatory bowel disease (IBD), according to a case series, as reported by Reuters. As many as 11.8% of patients with IBD can develop ophthalmological compl
- RAZ Mobility Launches Accessible Mobile Phone for Individuals with Impaired Visionhttps://modernod.com/news/raz-mobility-launches-accessible-mobile-phone-for-individuals-with-impaired-vision/2476607/RAZ Mobility has announced the launch of the Lucia, a mobile phone specifically designed to address the unique needs of people who are blind, low vision, or hard of hearing. Someone who is completely blind can use Lucia just as fully and effectively as someone who is sighted. According to
- Biophytis Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/biophytis-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2476604/Biophytis announced that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (SEC) in relation to a proposed initial public offering of American Depositary Shares representing ordinary shares of Biophytis. Biophytis has applied to list its shares
- Ocular Therapeutix OTX-TP Intracanalicular Insert Fails to Meet Phase 3 Endpointhttps://modernod.com/news/ocular-therapeutix-otx-tp-intracanalicular-insert-fails-to-meet-phase-3-endpoint/2476598/Ocular Therapeutix’s intracanalicular insert failed to meet its primary endpoint of statistically significant superiority in mean reduction of IOP compared with placebo at all nine time points, according to a company news release. OTX-TP is an intracanalicular insert that delivers a
- Patients Equally Pleased With Different Keratoplasty Approacheshttps://modernod.com/news/patients-equally-pleased-with-different-keratoplasty-approaches/2476586/Although the Descemet Endothelial Thickness Comparison Trial (DETECT) showed better visual acuity with a newer, more demanding corneal transplantation method, this did not translate into greater patient satisfaction, according to a secondary analysis of outcome data, as